As for overall survival (OS), high levels of YAP1 could be considered an unfavorable biomarker for LGG patients (n = 514, Log-rank p = 0.0069, HR = 1.7; Supplementary Figure S1A), PAAD patients (n = 178, Log-rank p = 0.0053, HR = 1.8; Supplementary Figure S1B) and ACC patients (n = 76, Log-rank p = 0.0064, HR = 36; Supplementary Figure S1C). This evidence concerns the gene YAP1 and pancreatic adenocarcinoma.